Search
Fenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalFenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia.
Mixtures: FENOVAS®10 MG, FENOVAS®10 MGProducts: TRILIPIX 135 MG, ACIDO FENOFIBRICO 135 MGSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Nexpovio 20 mg Film Kaplı Tablet, 8 TABLET, Nexpovio 20 mg Film Kaplı Tablet, 12 TABLETVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MG, ZELBORAF 240 MG FILM KAPLI TABLET ,56 FILM KAPLI TABLETFlutamide
go.drugbank.com/drugs/DB00499ApprovedInvestigationalAn antiandrogen with about the same potency as cyproterone in rodent and canine species.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: α,α,α-trifluoro-2-methyl-4'-nitro-m-propionotoluidideErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationaltool kit to treat such a prevalent medical condition. … [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: BALVERSA 3 MG FİLM KAPLI TABLET, 56 ADET, BALVERSA 3 MG FİLM KAPLI TABLET, 84 ADETMefloquine
go.drugbank.com/drugs/DB00358ApprovedMalaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.
Mixtures: อาร์ทีซูเนทและเมฟลอควินไฮโดรคลอไรด์ 100/220 มก.Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: TAGRISSO® 40 MG, TAGRISSO® 80 MG.Chlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedA centrally acting central muscle relaxant with sedative properties.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: PARAFLEX 250 MG TABLET, 20 ADET, PARAFLEX 250 MG TABLET, 500 ADETBromazepam
go.drugbank.com/drugs/DB01558ApprovedIllicitIt is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: BROMAZEPAM AL 6, BROMAZEPAM 6 1A PHARMA